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Double umbilical cord blood (dUCB) allogeneic transplantation after a low-dose total body irradiation,
cyclophosphamide, and ﬂudarabine (TCF)ebased reduced-intensity conditioning regimen (RIC) is increas-
ingly used in adults lacking a suitable related or unrelated donor. Currently, there are little data regarding
the long-term outcome of CD3þ T cell chimerism (TCC) in this particular setting. Thirty-six adults with
various hematological diseases who received dUCB allogeneic transplants conditioned with TCF were
included in this retrospective study. Peripheral blood CD3þ TCC was considered until day þ100 after
transplantation to determine the impact of full versus mixed chimerism on long-term outcomes. Twenty-
nine and 7 patients were documented with full and mixed CD3þ TCC, respectively, within the ﬁrst 100 days
after transplantation. With a median follow-up of 36 months, 3 year-overall survival (OS), disease-free
survival (DFS), and cumulative incidence of relapse (CIR) were 61%, (95% conﬁdence interval [CI], 43% to
75%); 50% (95% CI, 32.5% to 66%), and 28% (95% CI, 16% to 44%), respectively. In univariate analysis, a full
CD3þ TCC was associated with a better 3-year DFS: 59% (95% CI, 39% to 75.5%) versus 14% (95% CI, 7% to
46%); hazard ratio (HR), .24 (.09 to .65); P ¼ .005 and a lower CIR: 24% (95% CI, 21.5% to 57%) versus 78% (95%
CI, 52% to 99%); HR, .18 (.05 to .50); P ¼ .004. In multivariate analysis, a full CD3þ TCC remained associated
with a lower CIR (HR, .17 [.028 to .99]; P ¼ .049). CD3þ TCC has no impact on graft-versus-host disease and
nonrelapse mortality in this study. In conclusion, here, full CD3þ TCC was independently associated with a
lower risk of relapse in adults receiving a dUCB TCF RIC allogeneic transplantation. This highlights the need
to develop immunotherapy approaches allowing for early conversion to full chimerism after this type of
transplantation.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION mixed chimerism is not clear, as residual host cells may
The goal of allogeneic transplantation for malignant he-
matological diseases is complete eradication of tumor cells
together with the development of complete donor chime-
rism. Chimerism is a measure of the number of donor and
recipient cells in the host after infusion of the allogeneic
stem cells. Among different techniques of measurement,
polymerase chain reaction of short tandem repeats using
ﬂuorescent ampliﬁcation is currently considered the most
sensitive method to detect donor cells [1]. Myeloablative
allotransplantations are generally associated with full donor
chimerism, whereas mixed chimerism occurs frequently af-
ter reduced-intensity conditioning (RIC) regimens or T
celledepleted allografts. At present, the signiﬁcance ofedgments on page 183.
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e Cellulaire, APHP, Paris, France.represent normal hematopoiesis without deleterious impact
on outcome. On the other hand, it may be also predictive of
secondary graft failure [2,3] or disease relapse due to the
persistence of host tumor cells together with a lower risk of
acute [4-6] or chronic graft-versus-host disease (GVHD) [7,8].
Thus, many investigators consider that patients with mixed
chimerism are potential candidates for adoptive immuno-
therapy. Another point to consider is whether the chimerism
is detected inwhole blood or bonemarrow and if it is lineage
speciﬁc. Currently, it is recommended to use peripheral
blood cells and lineage-speciﬁc chimerism, especially CD3þ T
cell chimerism (TCC), as a more sensitive assay, especially in
the nonmyeloablative setting [9].
Double umbilical cord blood (dUCB) transplantation after
RIC represents a valid option for curing adult patients with
hematological disorders without related or unrelated donors
[10-12]. The so-called TCF RIC regimen developed by the
Minneapolis group is 1 of the most widely used regimens for
these patients [13]. It combines low-dose total body irradi-
ation (2 Grays), cyclophosphamide 50 mg/kg for 1 day, and
ﬂudarabine 40 mg/m2 for 5 days (200 mg/m2 total dose) and
provides similar results compared with peripheral blood
stem cells RIC allogeneic transplantation [14]. Among factors
that could inﬂuence outcomes after dUCB allotransplant in
Table 1
Patients, Sustained Cord Blood, and Transplantation Characteristics
Characteristic Full TCC (n ¼ 29) Mixed TCC (n ¼ 7) P Value
No. of Patients % No. of Patients %
Patients characteristics
Age at transplantation, median (range), yr 57 (22-69) 47 (17-64) NS
Sex: female 14 48 3 43 NS
Hematological malignancy: Lymphoid/myeloid 14/15 48/52 3/4 43/57 NS
Status at transplantation: CR/PR 23/6 79/21 6/1 86/14 NS
Time to transplantation, median (range), d 395 (137-5645) 216 (92-604) NS
Cord blood characteristics
Age of cord blood, median (range), mo 31 (9-165) 116 (23-140) NS
Matching cordon with patient NS
4/6 10 35 3 43
5/6 19 65 3 43
6/6 0 0 1 14
Number of TNC before and after thawing, respectively,
median (range), 108/kg
.28 (.16-.455); .248 (.157-.406) .222 (.135-.492); .22 (.11-.392) NS
Number of CD34þ cell before and after thawing,
respectively, median (range), 106/kg
.066 (.022-.215); .043 (.02-.2) .078 (.031-.427); .041 (.019-.259) NS
Mismatch between cord blood and patient
Sex 14 48 3 43 NS
Serology CMV 13 45 3 43 NS
ABO 16 55 2 28 NS
Rhesus 22 76 6 86 NS
Graft
Neutrophil count recovery >.5 g/L, median (range), d 17 (6-32) 11 (7-20) NS
Platelet recovery > 20 g/L, median (range), d 41 (0-164) 31 (0-67) NS
Acute GVHD (grade II-IV/grade III-IV) 19 (12/6) 65 (41/21) 4 (3/1) 57 (43/14) NS
Chronic GVHD (Limited/extensive) 11 (8/3) 38 (28/10) 3 (2/1) 43 (28/14) NS
Chimerism
Rate, median (range), % 100 (96-100) 82 (14-94) <.001
NS indicates not signiﬁcant; CR, complete remission; PR, partial remission; CMV, cytomegalovirus.
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Indeed, if a favorable impact of full donor chimerism on
hematopoietic recovery or pre-engraftment syndrome has
been already reported, no data regarding inﬂuence of mixed
versus full TCC chimerism on long-term outcomes are yet
available after dUCB RIC transplantations in adults [15,16].
This study aimed to investigate the inﬂuence of full versus
mixed TCC on various outcomes in a cohort of adult patients
who engrafted after a standard dUCB TCF allotransplantation.PATIENTS AND METHODS
Study Design, Patients’ Characteristics, and Graft Selection Criteria
All adult patients (17 to 70 years old) in our institution who engrafted
after a dUCB TCF allotransplantation and for whom at least 1 TCC was
assessed within the ﬁrst 100 days after transplantation were eligible for this
study. TCF is a RIC combining low-dose (2 Grays) total body irradiation,
cyclophosphamide 50 mg/kg for 1 day, and ﬂudarabine 40 mg/m2 for 5 days
(200 mg/m2 total dose). Between June 2008 and March 2013, we performed
58 dUCB allotransplantations in our department. Among these 58 cases, only
36 patients who met the inclusion criteria for the study were identiﬁed.
Twenty-two cases were not considered because they had not received the
TCF regimen as conditioning or they had not been assessed for T cell
chimerism within the ﬁrst 100 days after transplantation. Overall, there
were 19males and 17 females. Median age for thewhole cohort was 57 years
(range, 17 to 69). Nineteen patients had myeloid diseases, including acute
myeloid leukemia in 17 andmyelodysplastic syndrome in 2 cases. Seventeen
patients had lymphoid diseases, including 16 lymphomas (large diffuse B
cell lymphoma [n ¼ 5], mantle cell lymphoma [n ¼ 2], Hodgkin disease
[n ¼ 2], B cell chronic lymphocytic leukemia [n ¼ 2], Waldenström disease
[n ¼ 1], peripheral T cell lymphoma [n ¼ 2], T cell prolymphocytic leukemia
[n ¼ 1], and angio-immunoblastic T cell lymphoma [n ¼ 1]) and 1 acute
lymphoblastic leukemia. Patients underwent transplantation in complete
remission (n ¼ 29) or partial remission (n ¼ 7). Fourteen patients have been
previously undergone transplantation (autologous stem cell transplantation
n ¼ 13; allogeneic stem cell transplantation n ¼ 1). The median interval
between diagnosis and graft was 10.5 months (range, 3 to 188).
All patients received cyclosporine and mycophenolate mofetil as GVHD
prophylaxis. According to local practice and in case of no GVHD develop-
ment, mycophenolate mofetil was tapered as early as day þ30 and stoppedat day þ60, whereas cyclosporine was progressively tapered to be stopped
between 4 to 6 months after transplantation.
Cord blood units were matched at greater than 3 of 6 HLA antigens
based on antigen-level HLA-A and -B typing and allele-level HLA-DRB1
typing. Also, sufﬁcient cryopreserved total nucleated cells (TNC) (>1.5107/
kg for each unit or total dose > 3  107/kg) was considered for the selection
of CB units for all patients. The median number of TNC (107/kg) and CD34þ
(106/kg) cells infused before and after thawing were .267 (range, .135 to
.492), .243 (range, .11 to .406), .071 (range, .022 to 0.427), and .042 (range,
.019 to .259), respectively.
All patients gave informed consent for retrospective studies and all data
were extracted from the European Society for Blood and Marrow Trans-
plantation registry. The main objective of the study was to investigate the
impact of full versus mixed TCC on survival, incidence of relapse, nonrelapse
mortality, and acute or chronic GVHD after dUCB TCF allotransplantation in
adults. Patients’ and transplantation characteristics are summarized in
Table 1.
Peripheral Blood CD3þ TCC
CD3þ TCC was studied on sorted peripheral blood CD3þ T lymphocytes
by quantitative-PCR evaluation of differential short tandem repeat DNA
sequences as previously described [17]. Full and mixed donor TCC were
deﬁned by the presence of at least 95% and between 6% and 94% of CD3þ
donor T cells, respectively, both units combined. Engraftmentwas deﬁned as
sustained neutrophil recovery with donor chimerism > 5%, both units
combined. Considering the 36 patients, 33 were evaluated for TCC at
day þ60 and 26 at day þ100 (10). Except for 13 cases, patients had not
been evaluated for TCC at day þ30 (10) because of deep lymphopenia.
Endpoints Deﬁnition
Survival was calculated from the date of transplantation until relapse or
death or last follow-up for disease-free survival (DFS) or to death or to last
follow-up for overall survival (OS). Cumulative incidence of relapse (CIR)
was calculated from the date of transplantation until relapse, taking into
account death from any other cause as a competing risk. Nonrelapse mor-
tality (NRM) was deﬁned as death from any cause without previous relapse
or progression. Acute and chronic GVHD were diagnosed and graded ac-
cording to standard criteria [18,19].
Statistical Analysis
Categorical variable comparisons were performed by the Fisher exact
test. Median comparisons were performed by the Mann-Whitney 2-sample
Table 2
Multivariate Analysis for DFS, OS, and CIR
Outcome HR 95% CI P Value
DFS
Age (continuous variable) .97 .93-1.01 .174
Sex .37 .10-1.26 .111
TCC full versus mixed .28 .074-1.04 .058
Chronic GVHD: no versus yes 4.68 1.12-19.53 .034
OS
Age (continuous variable) .95 .91-.99 .022
Myeloid versus lymphoid 9.13 1.7-49.05 .010
Acute GVHD: none versus grade 3-4 .24 .06-.93 .038
TCC full versus mixed .62 .15-2.46 .495
CIR
Age (continuous variable) .95 .91-1.00 .057
Sex .88 .15-5.26 .892
TCC full versus mixed .17 .028-.99 .049
Chronic GVHD: no versus yes 8.19 .46-146.41 .153
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univariate and multivariate Cox hazard ratio models. For CIR, the same
variables were tested using the Gray test.
The Cox univariate and log rank tests were used for univariate com-
parisons. The following parameters were taken into account for analyses of
prognostic factors for survival: age; gender; type of diseases (ie, lymphoid
versus myeloid); status at transplantation; HLA matching of the engrafted
cord blood unit with recipient, number of TNC, and CD34þ cells infused
before and after thawing (< or > median); acute GVHD grade 2 to 4 and
grades 3 and 4; chronic GVHD; and full versus mixed TCC.
All factors associated with a P value < .20 by univariate analysis were
included in multivariate analyses, as well as chronic GVHD for DFS (P ¼ .261
in univariate analysis). Multivariate analyses were performed using the Cox
model. Statistical analyses were performed using STATA software package.
RESULTS
Evaluation of TCC after Transplantation within the First
100 Days after Transplantation
All patients were evaluated at least 1 time for TCC after
transplantation, whereas 24 were evaluated twice. The rea-
sons for not being evaluated were mainly GVDH occurrence
(n ¼ 6) or technical problems with the technical assay
(n ¼ 6). If more than 1 TCC was researched, the earliest
documentation of 1 full TCC was sufﬁcient to assign patients
in the complete donor TCC group. Thus, 29 cases were
assigned to this former group (median donor TCC, 100%;
range, 96% to 100%), whereas 7 cases were assigned to the
mixed donor TCC group (median TCC, 82%; range, 14% to
94%). There were no differences between groups (Table 1). At
time of TCC analyses, only 1 unit was detected in all cases and
was accountable for engraftment.
Outcomes and Factors Inﬂuencing Outcomes (excluding
TCC) after dUCB TCF Allotransplantation
With a median follow-up of 36 months, 3 year-OS, DFS,
and CIR were 61%, (95% conﬁdence interval [CI], 43% to 75%);
50% (95% CI, 32.5% to 66%), and 28% (95% CI, 16% to 44%),
respectively. NRM was 3% at day 100 and 14% at 1 year.
Incidences of grade 2 to 4 and grades 3 to 4 acute GVHDwere
42% and 19.5%, respectively. Incidence of chronic GVHD was
39% (limited 28%, extensive 11%).
In univariate analysis, a younger age (studied as a
continuous variable) was associated with a better DFS (haz-
ard ration [HR], .96; 95% CI, .93 to .99; P ¼ .04). No other
factor was associated with better DFS, OS, or lower CIR in this
study.
In multivariate analysis (Table 2), absence of chronic
GVHD was associated with lower DFS (HR, 4.68; 95% CI, 1.12
to 19.53; P ¼ .034). No grade 3 or 4 GVHD occurrence after
transplantation and younger ager were independently
associated with better OS (HR, .24; 95% CI, .06 to .93; P ¼ .03;
and HR, .95; 95% CI, .91 to .99; P ¼ .02), respectively. On the
contrary, a myeloid disease was associated with lower OS
(HR, 9.13; 95% CI, 1.7 to 49.05; P ¼ .01). No factor was
associated with relapse incidence in the multivariate
analysis.
Inﬂuence of Donor TCC within the First 100 Days after a
dUCB TCF Allotransplantation in Adults
In univariate analysis, documentation of at least 1 full
donor TCC within the ﬁrst 100 days after transplantationwas
associated with better DFS (Figure 1A) (3-year DFS, complete
donor TCC: 59% [95% CI, 39% to 75.5] versus mixed TCC: 14%
[95% CI, 7% to 46%]; HR, .24; 95% CI, .09 to .65; P ¼ .005), and
lower incidence of relapse (Figure 1B) (3-year CIR, complete
donor TCC: 24% [95% CI, 21.5% to 57%] versus mixed TCC: 78%
[95% CI, 52% to 99%]; HR, .18; 95% CI, .05 to .5; P ¼ .004). Inmultivariate analysis, full donor TCC remained indepen-
dently associated with lower relapse incidence (HR, .17; 95%
CI, .029 to .99; P ¼ .049). Relapse occurred in median 51 days
(range, 21 to 781) after the assessment of mixed TCC.
TCC has no inﬂuence on hematopoietic recoveries
(neutrophils or platelets), OS, NRM, or acute and chronic
GVHD incidences in this series.
DISCUSSION
Our study showed that documentation of a mixed donor
TCC within the ﬁrst 100 days after transplantation is asso-
ciated with a higher risk of relapse in adult patients receiving
a standard dUCB TCF RIC allo-transplantation. Mixed donor
TCC is probably also associated with lower DFS, but because
of the small size of the population, the P value did not reach
signiﬁcance in our study in multivariate analysis. Although
retrospective, our series has the advantage of studying a
homogeneous population in terms of conditioning, number
of cord blood units transplanted (double), patients (adults
only), GVHD prophylaxis, type of hematological disorders
(malignant only), and conﬁrmed previous results observed
after RIC transplantation using other source of stem cells
[4-6]. Of note, when comparing characteristics of the en-
grafted unit between groups, no differences were observed,
suggesting no inﬂuence of the winning unit in term of full or
mixed chimerism in this study.
Two studies have previously looked at the inﬂuence of
chimerism in the setting of cord blood transplantations. In
the ﬁrst, Berlung et al. found an association between com-
plete donor TCC and higher incidence of acute GVHD. No
associationwas found between TCC and other outcomes [20].
However, the population was very heterogeneous, as they
included pediatric or adult patients with tumoral or benign
hematological diseases, and mesenchymal stem cells were
used as GVHD prophylaxis. The second study, by Elkaim et al.,
considered single umbilical cord blood myeloablative trans-
plantation in 94 children and found that documentation of a
full donor chimerism, performed on whole peripheral blood
cells, was predictive of higher incidence of GVHD but with no
inﬂuence on relapse [21]. Thus, our series is the ﬁrst to
document the inﬂuence of TCC in the setting of dUCB
TCF allotransplantation, which is currently a standard of care
for adults lacking a suitable donor and eligible for
allotransplantation.
A diagnosis of myeloid disease was associated with lower
OS in our study. One can hypothesize that in case of
lymphoid diseases, where prognosis is better, normal
Figure 1. (A) At 3 years, DFS was estimated at 59% (95% CI, 39% to 75.5%) in
the full donor TCC group versus 14% (95% CI, 7% to 46%) in the mixed TCC
group; HR, .24; 95% CI, .09 to .65; P ¼ .005. (B) At 3 years, CIR was estimated a
24% (95% CI, 21.5% to 57%) in the full donor TCC group versus 78% (95% CI, 52%
to 99%) in the mixed TCC group; HR, .18; 95% CI, .05 to .5; P ¼ .004.
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required to avoid too much GVHD, whereas in case of more
aggressive disease, such as acute myeloid leukemia or acute
lymphoblastic leukemia, with a mixed TCC within the
ﬁrst 100 days after transplantation, withdrawal of the
drugs should be conducted more rapidly. The question of
immunotherapy allowing for early conversion to full donor
chimerism after umbilical cord blood allotransplantation
should be also explored in the future. For example, Tomizawa
et al. expanded CD4þ T lymphocytes from a residue of the
cord blood unit used for transplantation. Donor cord blood
lymphocytes infusion in patients improved conversion to a
full donor chimerism after transplantation [22].
Finally, advanced aged was associated with worse overall
survival in our series. It conﬁrms the worse prognosis of
older patients after umbilical cord blood allotransplantation,
as reported by Labopin et al. recently [23].
In conclusion, in our study, documentation of a complete
donor CD3þ TCC is independently associated with a lower
risk of relapse in adults receiving a standard dUCB TCF RIC
allotransplantation. These results should be conﬁrmed by
other studies, and immunotherapy, allowing for early con-
version to full donor chimerism after this type of graft,
should be developed in the future.
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cell transplantationa b s t r a c t
Despite the successes of tyrosine kinase inhibitors (TKIs) in improving outcomes in patients with chronic
myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph þ ALL), allogeneic
hematopoietic stem cell transplantation (HSCT) continues to be an important and potentially curative option
for selected patients with either disease. After HSCT, TKIs are increasingly being used to treat or prevent
disease relapse, and practice patterns suggest that these TKIs are often chosen empirically without regard to
pre-HSCT mutation status. We investigated whether ABL kinase domain mutations persist after trans-
plantation and, thus, whether pre-HSCT mutation status should inform the selection of post-HSCT TKIs in
these patients. We retrospectively analyzed adults who underwent allogeneic HSCT for CML and Ph þ ALL at
our institution between 2000 and 2010, and we identiﬁed subjects who had detectable BCR-ABL transcripts
by polymerase chain reaction (PCR), as well as available RNA for Sanger sequencing of the ABL kinase domain,
in both the pre- and post-HSCT settings. In total, 95 CML and 20 Ph þ ALL patients with positive PCR tran-
scripts were identiﬁed, of which 10 (10.5%) and 4 (20.0%), respectively, were found to have pre-HSCT ABL
kinase mutations known to confer TKI resistance. In 9 (64.2%) of these 14 patients, the same kinase mutation
was also detectable at an average time of 191 days after HSCT. Seven (50.0%) of the 14 harboring mutations
had relapsed/refractory disease by last follow-up, of which, in retrospect, 6 had received a predictably
ineffective TKI within the ﬁrst 100 days after transplantation based on our mutation analysis. These data
support the idea that pre-existing mutations in the ABL kinase domain, frequently associated with resistance
to TKIs and prevalent in a transplantation population, are persistently detectable in the majority of patients
after transplantation. We propose that such resistance patterns should be considered when selecting TKIs in
the post-HSCT setting, including clinical trials of post-HSCT TKI prophylaxis.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION In the current treatment approach for CML, allogeneic
Tyrosine kinase inhibitors (TKIs) remain the front-line
therapy for patients with chronic myeloid leukemia (CML)
and also improve outcomes when incorporated into induc-
tion and maintenance regimens for those with Philadelphia-
positive acute lymphoblastic leukemia (Phþ ALL). Resistance
to TKIs is commonly due to the emergence of clones con-
taining point mutations in the ABL kinase domain of BCR-
ABL, occurring in as many as 30% to 60% of CML patients
with imatinib resistance [1,2], as well as in over one third of
Ph þ ALL patients at the time of diagnosis [3]. More than 100
ABL kinase domain mutations associated with TKI resistance
have been described [4].hematopoietic stem cell transplantation (HSCT) is generally
reserved for patients who fail or are intolerant of TKI therapy
or for those with advanced phase disease. Transplantation is
also a potentially curative option for Ph þ ALL patients with
HLA identically matched related or unrelated donors. Relapse
after HSCT is fairly common in both advanced phase CML
(30% to 40%) [5,6] and Ph þ ALL (30% to 60%) [7]. Therapeutic
strategies to treat post-HSCT relapse historically consisted of
withdrawal of immunosuppression or donor lymphocyte
infusions, though several studies have shown efﬁcacy in
treating relapsed CML or Ph þ ALL with TKIs [8-15]. An
increasing number of studies have also evaluated the pro-
phylactic use of TKIs after transplantation in high-risk pa-
tients, including those with detectable BCR-ABL at the time
of transplantation, though there are very limited data to
guide their selection and administration [16-19].
In addition to cost considerations, the selection of post-
transplantation TKIs is based, at least in part, on toxicity
proﬁles of the available agents. The bulk of retrospective
and prospective studies using imatinib indicate that it is
generally well-tolerated after HSCT, even in the early
